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Abstract. Sinusoidal obstruction syndrome (SOS), previously 
known as veno-occlusive disease, is relatively rare subsequent 
to liver transplantation (LT). SOS refractory to medical therapy, 
however, can result in centrilobular fibrosis, portal hypertension 
and liver failure. Although sinusoidal endothelial cell damage 
around central venules (zone 3) occurs early in the development 
of SOS, the detailed mechanism of SOS development and its 
association with thrombocytopenia are not yet completely 
understood. The present report describes a patient who experi-
enced SOS with unexplained thrombocytopenia following living 
donor LT. The progression of SOS resulted in graft dysfunction 
and the patient succumbed. The presence of platelets in the liver 
allograft was assayed immunohistochemically using antibody 
to the platelet marker cluster of differentiation 42b (platelet 
glycoprotein Ib). Platelet aggregates were found attached to 
hepatocytes along the sinusoid and within the cytoplasm of 
hepatocytes, particularly in zone 3. By contrast, no staining was 
observed in zone 1. These findings suggested that extravasated 
platelet aggregation in the space of Disse and the phagocytosis 
of platelets by hepatocytes were initiated by sinusoidal endothe-
lial cell damage due to the toxicity of the immunosuppressant 
tacrolimus or a corticosteroid pulse, and that platelet activation 
and degranulation may be at least partially involved in the 
mechanism responsible for SOS.
Introduction
Sinusoidal obstruction syndrome (SOS), a condition previ-
ously known as veno-occlusive disease (1), is a life-threatening 
syndrome that results from sinusoidal congestion and is 
characterized by hepatomegaly, ascites, portal hypertension, 
weight gain and jaundice (2). This syndrome is commonly 
observed as a complication of high-dose chemotherapy 
administered prior to hematopoietic progenitor cell (HPC) 
transplantation (3). The development of SOS subsequent to 
liver transplantation (LT) is relatively uncommon, being 
observed in ~2% of LT recipients (4). SOS is severe and 
refractory to medical therapy, with the ultimate solution 
being re-transplantation (2).
The mechanism underlying the development of SOS is not 
yet completely understood, although sinusoidal endothelial 
cell damage leading to alterations in the hemostatic system 
is regarded as central to the pathogenesis of SOS (5). SOS 
has additionally been reported to be associated with platelet 
functions. For example, transforming growth factor (TGF) β-1 
secreted by platelets has been shown to contribute to hyper-
coagulability in SOS following HPC transplantation (6). In 
addition, plasminogen activator inhibitor-1 (PAI-1), which 
is abundant in platelets, has been suggested to be a specific 
marker of SOS (7). Clinically, patients who experience SOS 
following HPC transplantation are both thrombocytopenic 
and refractory to platelet transfusions (8). These observations 
suggest that platelets may be important in the pathogenesis of 
SOS.
The present case report describes a patient who experienced 
liver allograft dysfunction caused by the progression of SOS 
following living donor LT (LDLT), with unexplained throm-
bocytopenia occurring around the same period of time. We 
hypothesized that the platelets had been consumed by the liver 
allograft, and therefore the allograft was immunohistochemi-
cally assayed for the presence of platelets using antibody to 
the platelet marker cluster of differentiation (CD)42b (platelet 
glycoprotein Ib).
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Case report
A 59-year-old male patient was diagnosed with primary 
biliary cirrhosis-autoimmune hepatitis overlap syndrome and 
end-stage cirrhosis. His Child-Pugh score was C 12 points and 
his Model For End-Stage Liver Disease score was 23 (9). The 
donor was the patient's 56-year-old wife. Their blood types 
were compatible (blood type O→AB), and the lymphocyte 
cross-match test was negative. The LDLT involved the right lobe 
without the middle hepatic vein (500 g). The graft-to-recipient 
weight ratio was 0.83, with the graft constituting 42% of the 
standard liver volume of the recipient. Following transplanta-
tion, the patient was started on immunosuppressive treatment 
with tacrolimus (Tac), mycophenolate mofetil (MMF) and 
prednisolone. His immediate postoperative course was good, 
and he was moved from the intensive-care unit on postopera-
tive day (POD) 3.
Approximately 2 months after the LDLT, the patient's 
concentrations of biliary tract enzymes and total bilirubin 
(T-Bil) began to increase progressively. Endoscopic retrograde 
cholangiopancreatography revealed no stenosis of the biliary 
anastomosis, and color doppler ultrasonography and computed 
tomography revealed no abnormalities. A liver biopsy on 
POD 77 showed minimal inflammation of the portal area and 
slight endothelial inflammation of the central venules. At that 
time, the patient's platelet counts were <10x105/mm3 and his 
T-Bil concentration continued to increase, to 17 mg/dl. The 
patient was regarded as experiencing late-onset acute rejection 
and was treated with augmented immunosuppressive therapy, 
consisting of intravenous corticosteroid pulse therapy, increased 
doses of MMF and adjustment of the Tac trough level to main-
tain a whole-blood concentration of 5-10 ng/ml. A liver biopsy 
taken on POD 91 showed minimal inflammation and no bile 
duct injury in the portal area (Fig. 1A), similar to the previous 
biopsy. Zone 3, however, showed chronic inflammation and a 
loss of hepatocytes (Fig. 1B). The sample was negative for C4d 
staining, a marker of antibody-mediated rejection. Based on 
these findings, the patient was diagnosed with late‑onset acute 
rejection accompanied by mild central perivenulitis, resulting in 
an intensification of immunosuppression. Since the concentra-
tion of Tac could not be maintained >10 ng/ml, despite increased 
doses, the patient's calcineurin inhibitor treatment was switched 
from Tac to cyclosporin A (CsA), with the CsA dose adjusted 
to maintain a target level in the blood of 150-200 ng/ml, and 
everolimus was added as a third immunosuppressive agent. In 
addition, the patient was administered two doses of basiliximab 
(50 mg/day) to suppress the antibody-mediated rejection. The 
patient's platelet counts declined to ~5x105/mm3, despite the 
lack of any apparent causes of the thrombocytopenia, such as 
disseminated intravascular coagulation, thrombotic microan-
giopathy or any other thrombotic diseases; however, his T-Bil 
concentration increased to 21.4 mg/dl. A liver biopsy taken 
on POD 203 showed inflammatory cells infiltrating the liver 
parenchyma in zone 3, as well as marked reductions in hepato-
cytes and central vein obliteration, as revealed by hematoxylin 
and eosin staining (Fig. 1C). Masson's trichrome stain showed 
basement membrane formation caused by fibrous tissue and 
sinusoidal fibrosis (Fig. 1D). By contrast, the portal area (zone 1) 
showed minimal inflammation, similar to the previous biopsy. 
The patient's central perivenulitis had progressively worsened, 
resulting in the development of SOS. His platelet count was 
~5x105/mm3, the allograft was less responsive to augmented 
immunosuppressive therapy and his condition was considered 
irreversible. Re-transplantation was indicated if feasible, but a 
donor could not be found. He subsequently experienced liver 
and renal failure and succumbed on POD 250.
Immunohistochemistry of CD42b. The presence of platelets in 
the liver tissue samples was assayed using a mouse monoclonal 
antibody to CD42b (1:100; cat. no. EPR6995; Abcam, Tokyo, 
Japan), a marker expressed on both inactive and activated plate-
lets. In normal spleen tissue, used as a positive control, CD42b 
expression was evident as dots, morphologically characterized 
as platelets (Fig. 2A), whereas there was no staining of normal 
liver tissue, used as the negative control (Fig. 2B). Assay of 
the liver allograft tissue obtained from the patient on POD 91 
showed CD42b expression in zone 3 (Fig. 3A). At greater 
magnification, the CD42b appeared as aggregates attached to 
hepatocytes along the sinusoids. CD42b was also expressed in 
the cytoplasm of the hepatocytes (Fig. 3B) but was not observed 
in zone 1.
Discussion
SOS is believed to result from sinusoidal endothelial cell 
damage in zone 3 of the liver (5). Red blood cells subsequently 
leak into the space of Disse, depositing fibrin (1). The base-
ment membrane that forms from the fibrous tissue leads to 
hepatocyte ischemia, followed by hepatocyte necrosis (1). 
Tac administration following transplantation may be due to 
sinusoidal endothelial cell damage of the small hepatic vein in 
zone 3 (10,11). To date, however, the pathophysiology of SOS 
remains incompletely understood, with no definitive mecha-
nisms or effective treatments identified.
There are few reports concerning a pathologic association 
between platelets and SOS. One study, in which liver samples 
taken at autopsy from HPC transplant recipients with SOS were 
stained with an anti-platelet antibody, found no evidence of 
platelet deposition (12); however, to prevent SOS, its pathogenetic 
mechanism must be clarified prior to it becoming irreversible. 
The present study therefore assessed liver tissue samples taken 
from an LDLT recipient in the development process of SOS. 
Zone 3 of the liver was positive for CD42b, with the staining 
pattern observed as aggregates attached to hepatocytes along the 
sinusoid and in the cytoplasm of the hepatocytes. These findings 
suggest that extravasated platelet aggregation (EPA) was present 
in the space of Disse, and that the platelets were phagocytized 
by hepatocytes. It is likely that these aggregated and activated 
platelets in the space of Disse had a greater influence on hepato-
cytes than did the platelets in the sinusoidal vessels.
Liver sinusoids are a type of sinusoidal blood vessel with 
endothelial fenestrations (13) (Fig. 4A), the diameters of which 
are increased by sinusoidal endothelial cell damage (14). The 
sinusoidal endothelial cells in the patient described in the 
present report had been exposed to Tac or a corticosteroid pulse, 
resulting in sinusoidal endothelial cell damage. This damage 
likely contributed to the denuding of the endothelium or loss of 
the fenestrations, allowing platelets to enter the space of Disse 
(Fig. 4B). This space contains reticulin fibers, most of which 
contain collagen type 3 (15). Platelets have been found to bind 
EXPERIMENTAL AND THERAPEUTIC MEDICINE  9:  1119-1124,  2015 1121
Figure 2. Immunohistochemical staining of (A) normal spleen and (B) normal liver with antibody to cluster of differentiation 42b. (A) Immunoreactivity was 
evident throughout the spleen as dots, which were morphologically characterized as platelets (magnification, x400). (B) No staining of normal liver tissue was 
observed (magnification, x200). C, central vein.
Figure 3. Immunohistochemical staining of liver allograft tissues with antibody to CD42b. (A) The liver biopsy taken on postoperative day 91 showed CD42b 
expression in zone 3 (magnification, x400). (B) At higher magnification, CD42b was present as aggregates attached to hepatocytes (arrowheads) along the 
sinusoid (★) and in the hepatocyte cytoplasm (arrows) (magnification, x1,000). C, central vein; H, hepatocyte; CD42b, cluster of differentiation 42b.
Figure 1. Histopathology of the liver biopsy sample obtained on POD 91 and 203 (magnification, x200). (A and B) Samples taken on POD 91 showing (A) min-
imal inflammation and no bile duct injury in the portal area and (B) chronic inflammation and loss of hepatocytes in zone 3 (hematoxylin and eosin staining). 
(C and D) Samples taken on POD 203 showing (C) inflammatory cells infiltrating into the liver parenchyma, severe loss of hepatocytes and central vein oblitera-
tion (hematoxylin and eosion staining) and (D) basement membrane formation caused by fibrous tissue and sinusoidal fibrosis, with progressive worsening of the 
central perivenulitis and the development of sinusoidal obstruction syndrome (Masson's trichrome stain). C, central vein; P, portal vein; POD, postoperative day.
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to and form aggregates with collagen type 3 (16), resulting in 
platelet aggregation in the space of Disse (Fig. 4B).
Hepatocytes contribute to blood homeostasis by endo-
cytosing a number of proteins present in plasma (17). The 
asialoglycoprotein receptor (ASGR), a membrane-bound 
lectin, removes the target glycoproteins from the circula-
tion (18). These glycoproteins are also found on the surface of 
platelets, and human platelets have been reported to be seques-
tered by hepatocytes through the ASGR (19). In the patient in 
the present report, the extravasated platelets in the space of 
Disse may have been phagocytized by hepatocytes through the 
ASGR (Fig. 4B).
Platelets contain α and dense granules (20). Upon activa-
tion, platelets excrete the contents of these granules into their 
canalicular systems or the surrounding blood (20). These 
granules also contain negative regulators of liver regenera-
tion, including thromboxane A2 (TXA2), vascular endothelial 
growth factor-A (VEGF-A), TGF-β and PAI-1 (6,21,22). TXA2 
is a vasoconstrictor that increases portal venous resistance (23) 
and causes portal hypertension. Although VEGF-A acts as 
Figure 4. Schematic model of (A) a normal sinusoid and (B) the sinusoid of sinusoidal obstruction syndrome in the patient in the present study. The normal 
sinusoid is a type of sinusoidal blood vessel with endothelial fenestrations (A). Damage to the sinusoidal endothelium can result in the denuding of the 
endothelium or the loss of fenestrations, allowing platelets to enter the space of Disse. This space contains reticulin fibers, which consist primarily of collagen 
type 3. Platelets can easily attach to collagen type 3, forming aggregates, including in the space of Disse. In addition, the extravasated platelets in the space of 
Disse can be phagocytized by hepatocytes through the asialoglycoprotein receptor (B).
Figure 5. The predicted pathogenic mechanism of SOS in the patient in the present study. Extravasated platelet aggregation in the space of Disse was initiated 
by damage to the sinusoidal endothelium induced by tacrolimus or a corticosteroid pulse. The negative regulators released by activated platelets, including 
TXA2, VEGF-A, PAI-1 and TGF-β, may have induced portal hypertension and the progression of hepatic fibrosis, as well as suppressed liver regeneration, 
initiating liver damage with SOS. SOS, sinusoidal obstruction syndrome; TXA2, thromboxane A2; VEGF-A, vascular endothelial growth factor-A; PAI-1, 
plasminogen activator inhibitor-1; HGF, hepatocyte growth factor; TGF-β, transforming growth factor-β.
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a vasodilator under ordinary circumstances, it acts, para-
doxically, as a vasoconstrictor in patients with endothelial 
failure (24). Bevacizumab, an antibody against VEGF-A, 
protects against liver injury associated with SOS (25). PAI-1 
suppresses fibrinolysis and the progression to fibrosis in the 
tissue microenvironment. In addition, PAI-1 acts as a negative 
regulator of hepatocyte proliferation by inhibiting uroki-
nase-type plasminogen activator, which activates hepatocyte 
growth factor (26,27). TGF-β is a major antiproliferative factor 
for hepatocytes (28) that stimulates collagen synthesis through 
activated hepatic stellate cells (29). In the patient in the present 
report, the release by platelets of these negative regulators 
may have induced portal hypertension and the progression of 
hepatic fibrosis, as well as the suppression liver regeneration, 
a mechanism responsible, at least in part, for the initiation of 
liver damage with SOS (Fig. 5).
No standard method of treating SOS has yet been estab-
lished. Systemic anticoagulation and thrombolytic therapies 
have been tested extensively (30). Defibrotide, a polydeoxyri-
bonucleic acid, has been recently shown to have a promising 
response rate in patients with severe SOS (31). When medical 
treatment fails, transjugular intrahepatic portosystemic 
shunt placement or re-transplantation can be considered (2). 
Depending on the extent of the sinusoidal endothelium damage 
and EPA in the space of Disse, the prophylactic administra-
tion of endothelial protective and antiplatelet agents may be 
effective prior to the development of irreversible damage. 
Cilostazol, a phosphodiesterase 3 (PDE3) inhibitor, may be 
appropriate, owing to its antiplatelet properties, its ability to 
increase tolerance to ischemia/reperfusion injury (32) and its 
induction of immune tolerance via an enhanced regulatory 
T-cell response (33). In clinical practice, we have administered 
a PDE3 inhibitor to LDLT recipients, with favorable outcomes 
(Nakanuma et al, unpublished data).
In conclusion, the present findings suggest that EPA in the 
space of Disse, which was initiated by sinusoidal endothelial 
cell damage due to the toxicity of Tac or a corticosteroid pulse 
and the negative regulators released by activated platelets, may 
have partially contributed to liver damage with SOS in the 
patient. Endothelial protective therapy or antiplatelet treatment 
may have been useful in the treatment of SOS in this patient. 
Studies in additional patients are necessary to elucidate the 
role of EPA in the space of Disse on the development of SOS.
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